Foundations Investment Advisors LLC Has $570,000 Holdings in Amgen Inc. (NASDAQ:AMGN)

Foundations Investment Advisors LLC boosted its stake in shares of Amgen Inc. (NASDAQ:AMGNGet Rating) by 22.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,325 shares of the medical research company’s stock after purchasing an additional 429 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Amgen were worth $570,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Amgen by 2.1% in the 4th quarter. BlackRock Inc. now owns 50,046,345 shares of the medical research company’s stock valued at $11,258,926,000 after buying an additional 1,032,929 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Amgen by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 47,329,045 shares of the medical research company’s stock valued at $11,445,110,000 after buying an additional 668,036 shares in the last quarter. State Street Corp raised its stake in shares of Amgen by 1.2% in the 1st quarter. State Street Corp now owns 30,504,420 shares of the medical research company’s stock valued at $7,376,579,000 after buying an additional 357,413 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Amgen by 1.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock valued at $2,132,778,000 after buying an additional 94,565 shares in the last quarter. Finally, Deutsche Bank AG raised its stake in shares of Amgen by 8.7% in the 4th quarter. Deutsche Bank AG now owns 5,660,218 shares of the medical research company’s stock valued at $1,273,380,000 after buying an additional 453,750 shares in the last quarter. 77.14% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Up 1.5 %

Shares of NASDAQ AMGN opened at $231.14 on Friday. The firm has a market capitalization of $123.64 billion, a PE ratio of 19.59, a price-to-earnings-growth ratio of 1.84 and a beta of 0.56. The company has a current ratio of 1.53, a quick ratio of 1.17 and a debt-to-equity ratio of 14.76. Amgen Inc. has a 1 year low of $198.64 and a 1 year high of $258.45. The firm’s 50-day moving average is $244.94 and its 200-day moving average is $243.47.

Amgen (NASDAQ:AMGNGet Rating) last announced its quarterly earnings results on Thursday, August 4th. The medical research company reported $4.65 earnings per share for the quarter, beating analysts’ consensus estimates of $4.40 by $0.25. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.53 billion. Amgen had a net margin of 24.92% and a return on equity of 218.34%. Amgen’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same period last year, the company posted $4.38 EPS. Equities analysts expect that Amgen Inc. will post 17.45 EPS for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Thursday, August 18th were given a $1.94 dividend. The ex-dividend date of this dividend was Wednesday, August 17th. This represents a $7.76 dividend on an annualized basis and a dividend yield of 3.36%. Amgen’s dividend payout ratio is 65.76%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. TheStreet upgraded shares of Amgen from a “c+” rating to a “b” rating in a research note on Monday, August 15th. Robert W. Baird reissued an “underperform” rating and set a $185.00 price objective on shares of Amgen in a report on Tuesday, September 13th. StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Monday, August 8th. Morgan Stanley increased their price objective on shares of Amgen from $239.00 to $253.00 and gave the stock an “equal weight” rating in a report on Friday, July 15th. Finally, Oppenheimer reissued an “outperform” rating and set a $290.00 price objective on shares of Amgen in a report on Wednesday. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $241.13.

Insider Activity at Amgen

In related news, Director R Sanders Williams sold 200 shares of the stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $249.96, for a total value of $49,992.00. Following the sale, the director now directly owns 5,301 shares in the company, valued at approximately $1,325,037.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Amgen news, Director R Sanders Williams sold 200 shares of the firm’s stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $249.96, for a total transaction of $49,992.00. Following the sale, the director now directly owns 5,301 shares in the company, valued at approximately $1,325,037.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert Eckert sold 6,600 shares of the firm’s stock in a transaction that occurred on Thursday, August 18th. The stock was sold at an average price of $249.00, for a total transaction of $1,643,400.00. Following the sale, the director now owns 21,184 shares in the company, valued at $5,274,816. The disclosure for this sale can be found here. 0.46% of the stock is currently owned by corporate insiders.

Amgen Profile

(Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Further Reading

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.